Summary of Study ST001223

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000820. The data can be accessed directly via it's Project DOI: 10.21228/M8PQ4V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001223
Study TitleHost Metabolic Response in Early Lyme Disease
Study SummaryLyme disease is a tick-borne bacterial illness that occurs in areas of North America, Europe, and Asia. Early infection typically presents as generalized symptoms with an erythema migrans (EM) skin lesion. Bacterial dissemination can result in multiple EM skin lesions or in extracutaneous manifestations such as Lyme neuroborreliosis. Metabolic biosignatures of patients with early Lyme disease can potentially provide diagnostic targets, as well as highlight metabolic pathways that contribute to pathogenesis. Sera from well-characterized patients diagnosed with either early localized Lyme disease (ELL) or early disseminated Lyme disease (EDL), plus healthy individuals (HC), from the United States were analyzed by liquid chromatography-mass spectrometry (LC-MS). Comparative analyses were performed between ELL, or EDL, or ELL combined with EDL, and the HC to develop biosignatures present in early Lyme disease. A direct comparison between ELL and EDL was also performed to develop a biosignature for stages of early Lyme disease. Metabolic pathway analysis and chemical identification of metabolites with LC-tandem mass spectrometry (LC-MS/MS) demonstrated alterations of eicosanoid, bile acid, sphingolipid, glycerophospholipid, and acylcarnitine metabolic pathways during early Lyme disease . These metabolic alterations were confirmed using a separate set of serum samples for validation. The findings demonstrated the metabolic pathways altered in the host during early Lyme disease and provide evidence that the diversity in the type of early Lyme disease manifestations may be associated with particular metabolic alterations.
Institute
Colorado State University
DepartmentDepartment of Microbiology, Immunology, and Pathology
LaboratoryBelisle
Last NameBelisle
First NameJohn
Address200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523
Emailjohn.belisle@colostate.edu
Phone9704915384
Submit Date2019-07-02
PublicationsHost Metabolic Response in Early Lyme Disease Bryna L. Fitzgerald, Claudia R. Molins, M. Nurul Islam, Barbara Graham, Petronella R. Hove, Gary P. Wormser, Linden Hu, Laura V. Ashton, and John T. Belisle Journal of Proteome Research 2020 19 (2), 610-623 DOI: 10.1021/acs.jproteome.9b00470
Analysis Type DetailLC-MS
Release Date2019-09-23
Release Version1
John Belisle John Belisle
https://dx.doi.org/10.21228/M8PQ4V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000820
Project DOI:doi: 10.21228/M8PQ4V
Project Title:Host Metabolic Response in Early Lyme Disease
Project Summary:LC-MS metabolomics analyses of early Lyme disease patient sera to identify host metabolic pathways altered from healthy controls as well as different early Lyme disease manifestations.
Institute:Colorado State University
Last Name:Belisle
First Name:John
Address:200 West Lake, Campus Delivery 0922, Colorado State University, Fort Collins, CO, 80523, USA
Email:john.belisle@colostate.edu
Phone:9704915384
Funding Source:U.S. NIH R33 AI-100228

Subject:

Subject ID:SU001290
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Sample Type
SA086294EL-NYMC-7-Run 2Early Disseminated Lyme
SA086295EL-NYMC-6-Run 1Early Disseminated Lyme
SA086296EL-NYMC-7-Run 1Early Disseminated Lyme
SA086297EL-NYMC-8-Run 2Early Disseminated Lyme
SA086298EL-NYMC-6-Run 2Early Disseminated Lyme
SA086299EL-NYMC-5-Run 2Early Disseminated Lyme
SA086300EL-NYMC-3-Run 1Early Disseminated Lyme
SA086301EL-NYMC-4-Run 2Early Disseminated Lyme
SA086302EL-NYMC-4-Run 1Early Disseminated Lyme
SA086303EL-NYMC-8-Run 1Early Disseminated Lyme
SA086304EL-NYMC-9-Run 1Early Disseminated Lyme
SA086305EL-NYMC-12-Run 2Early Disseminated Lyme
SA086306EL-NYMC-12-Run 1Early Disseminated Lyme
SA086307EL-NYMC-13-Run 2Early Disseminated Lyme
SA086308EL-NYMC-13-Run 1Early Disseminated Lyme
SA086309EL-NYMC-11-Run 1Early Disseminated Lyme
SA086310EL-NYMC-11-Run 2Early Disseminated Lyme
SA086311EL-NYMC-3-Run 2Early Disseminated Lyme
SA086312EL-NYMC-10-Run 2Early Disseminated Lyme
SA086313EL-NYMC-10-Run 1Early Disseminated Lyme
SA086314EL-NYMC-9-Run 2Early Disseminated Lyme
SA086315EL-NYMC-2-Run 2Early Disseminated Lyme
SA086316EL-NYMC-166-Run 4Early Disseminated Lyme
SA086317EL-NYMC-167-Run 3Early Disseminated Lyme
SA086318EL-NYMC-167-Run 4Early Disseminated Lyme
SA086319EL-NYMC-168-Run 3Early Disseminated Lyme
SA086320EL-NYMC-166-Run 3Early Disseminated Lyme
SA086321EL-NYMC-165-Run 4Early Disseminated Lyme
SA086322EL-NYMC-164-Run 3Early Disseminated Lyme
SA086323EL-NYMC-164-Run 4Early Disseminated Lyme
SA086324EL-NYMC-165-Run 3Early Disseminated Lyme
SA086325EL-NYMC-168-Run 4Early Disseminated Lyme
SA086326EL-NYMC-169-Run 3Early Disseminated Lyme
SA086327EL-NYMC-172-Run 3Early Disseminated Lyme
SA086328EL-NYMC-172-Run 4Early Disseminated Lyme
SA086329EL-NYMC-1-Run 2Early Disseminated Lyme
SA086330EL-NYMC-1-Run 1Early Disseminated Lyme
SA086331EL-NYMC-171-Run 4Early Disseminated Lyme
SA086332EL-NYMC-171-Run 3Early Disseminated Lyme
SA086333EL-NYMC-169-Run 4Early Disseminated Lyme
SA086334EL-NYMC-170-Run 3Early Disseminated Lyme
SA086335EL-NYMC-170-Run 4Early Disseminated Lyme
SA086336EL-NYMC-14-Run 2Early Disseminated Lyme
SA086337EL-NYMC-15-Run 2Early Disseminated Lyme
SA086338EL-NYMC-128-Run 1Early Disseminated Lyme
SA086339EL-NYMC-124-Run 1Early Disseminated Lyme
SA086340EL-NYMC-124-Run 2Early Disseminated Lyme
SA086341EL-NYMC-122-Run 1Early Disseminated Lyme
SA086342EL-NYMC-129-Run 2Early Disseminated Lyme
SA086343EL-NYMC-129-Run 1Early Disseminated Lyme
SA086344EL-NYMC-133-Run 2Early Disseminated Lyme
SA086345EL-NYMC-132-Run 1Early Disseminated Lyme
SA086346EL-NYMC-132-Run 2Early Disseminated Lyme
SA086347EL-NYMC-122-Run 2Early Disseminated Lyme
SA086348EL-NYMC-121-Run 1Early Disseminated Lyme
SA086349EL-NYMC-118-Run 1Early Disseminated Lyme
SA086350EL-NYMC-118-Run 2Early Disseminated Lyme
SA086351EL-NYMC-128-Run 2Early Disseminated Lyme
SA086352EL-NYMC-16-Run 2Early Disseminated Lyme
SA086353EL-NYMC-119-Run 2Early Disseminated Lyme
SA086354EL-NYMC-119-Run 1Early Disseminated Lyme
SA086355EL-NYMC-121-Run 2Early Disseminated Lyme
SA086356EL-NYMC-120-Run 1Early Disseminated Lyme
SA086357EL-NYMC-120-Run 2Early Disseminated Lyme
SA086358EL-NYMC-133-Run 1Early Disseminated Lyme
SA086359EL-NYMC-134-Run 2Early Disseminated Lyme
SA086360EL-NYMC-146-Run 2Early Disseminated Lyme
SA086361EL-NYMC-145-Run 1Early Disseminated Lyme
SA086362EL-NYMC-145-Run 2Early Disseminated Lyme
SA086363EL-NYMC-144-Run 1Early Disseminated Lyme
SA086364EL-NYMC-146-Run 1Early Disseminated Lyme
SA086365EL-NYMC-147-Run 2Early Disseminated Lyme
SA086366EL-NYMC-163-Run 4Early Disseminated Lyme
SA086367EL-NYMC-15-Run 1Early Disseminated Lyme
SA086368EL-NYMC-147-Run 1Early Disseminated Lyme
SA086369EL-NYMC-144-Run 2Early Disseminated Lyme
SA086370EL-NYMC-143-Run 2Early Disseminated Lyme
SA086371EL-NYMC-136-Run 2Early Disseminated Lyme
SA086372EL-NYMC-135-Run 1Early Disseminated Lyme
SA086373EL-NYMC-135-Run 2Early Disseminated Lyme
SA086374EL-NYMC-134-Run 1Early Disseminated Lyme
SA086375EL-NYMC-136-Run 1Early Disseminated Lyme
SA086376EL-NYMC-141-Run 2Early Disseminated Lyme
SA086377EL-NYMC-142-Run 1Early Disseminated Lyme
SA086378EL-NYMC-142-Run 2Early Disseminated Lyme
SA086379EL-NYMC-141-Run 1Early Disseminated Lyme
SA086380EL-NYMC-14-Run 1Early Disseminated Lyme
SA086381EL-NYMC-5-Run 1Early Disseminated Lyme
SA086382EL-NYMC-178-Run 4Early Disseminated Lyme
SA086383EL-NYMC-26-Run 2Early Disseminated Lyme
SA086384EL-NYMC-26-Run 1Early Disseminated Lyme
SA086385EL-NYMC-27-Run 2Early Disseminated Lyme
SA086386EL-NYMC-178-Run 3Early Disseminated Lyme
SA086387EL-NYMC-177-Run 4Early Disseminated Lyme
SA086388EL-NYMC-175-Run 4Early Disseminated Lyme
SA086389EL-NYMC-163-Run 3Early Disseminated Lyme
SA086390EL-NYMC-176-Run 4Early Disseminated Lyme
SA086391EL-NYMC-177-Run 3Early Disseminated Lyme
SA086392EL-NYMC-27-Run 1Early Disseminated Lyme
SA086393EL-NYMC-28-Run 2Early Disseminated Lyme
Showing page 1 of 6     Results:    1  2  3  4  5  Next  Last     Showing results 1 to 100 of 518

Collection:

Collection ID:CO001284
Collection Summary:Sera from early Lyme disease patients were collected pretreatment at the initial visit to the clinic. Healthy control serum donors were from endemic and non-endemic regions for Lyme disease.
Sample Type:Blood (serum)

Treatment:

Treatment ID:TR001305
Treatment Summary:N/A

Sample Preparation:

Sampleprep ID:SP001298
Sampleprep Summary:Small molecule metabolites were extracted from sera and analyzed by LC-MS as previously described. Specifically, cold methanol (60 µl) was added to 20 µl of sera, vortexed and incubated at -20°C for 1 h. Samples were warmed to room temperature for ten minutes, vortexed and centrifuged at 18,000 x g for 30 min. The supernatant (65 µl) was transferred to a new microcentrifuge tube and dried under vacuum. The dried metabolite extract was suspended in 50% methanol (40 µl) centrifuged at 18,000 x g for 15 min. An aliquot (35 µl) was transferred to an autosampler vial for LC-MS analysis.
Sampleprep Protocol Comments:doi:10.1038/nprot.2011.335

Combined analysis:

Analysis ID AN002036
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 6520
Column Poroshell 120 EC-C8 (100 x 2.1mm,2.5um)
MS Type ESI
MS instrument type QTOF
MS instrument name Agilent 6520 QTOF
Ion Mode POSITIVE
Units Peak Area

Chromatography:

Chromatography ID:CH001476
Instrument Name:Agilent 6520
Column Name:Poroshell 120 EC-C8 (100 x 2.1mm,2.5um)
Column Temperature:50
Flow Gradient:2-98% non-linear gradient
Flow Rate:0.25 ml/min
Solvent A:100% water; 0.1% formic acid
Solvent B:100% acetonitrile; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS001888
Analysis ID:AN002036
Instrument Name:Agilent 6520 QTOF
Instrument Type:QTOF
MS Type:ESI
MS Comments:Agilent MassHunter Qualitative Analysis software ultized for feature detection, Agilent Mass Profiler Professional utilized for feature filtering, and Agilent MassHunter Quantitative analysis software utilized for acquiring feature abundances.
Ion Mode:POSITIVE
Capillary Voltage:4000
Dry Gas Flow:10 l/min
Dry Gas Temp:310
Fragment Voltage:120
Nebulizer:45 psi
Octpole Voltage:750 V
Scanning Range:75-1700
Skimmer Voltage:65 V
  logo